FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Burow Kristina				2. Issuer Name and Ticker or Trading Symbol Unity Biotechnology, Inc. [UBX]					(Ch	eck all applic	cable) or	ng Person(s) to Iss		wner		
(Last) (First) (Middle) C/O UNITY BIOTECHNOLOGY, INC. 285 EAST GRAND AVENUE				3. Date of Earliest Transaction (Month/Day/Year) 06/24/2021							officer below)	cer (give title ow)		Other (specify below)		
(Street) SOUTH FRANCI (City)	SCO		94080 (Zip)	4.	If Amer	ndment, I	Date (of Original File	ed (Month/Da	ay/Year)	Line	X Form f	led by One lied by More	Reportin	Persor	1
		Tab	le I - Non-D	Perivativ	e Sec	curities	s Ac	quired, Di	sposed c	f, or Be	neficiall	y Owned				
Date			Transactior ate lonth/Day/Y	Execution Date,		Code (Instr. 5)			ed (A) or tr. 3, 4 and	5. Amour Securitie Beneficia Owned F Reported	s ally following	6. Owners Form: Dir (D) or Ind (I) (Instr. 4	ect (rect (7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s) and 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, Turity or Exercise (Month/Day/Year) if any		Code	ansaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year) (Month/Day/Year) 7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ow For Dire or I (I) (Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$4.18	06/24/2021		A		25,000		(1)	06/23/2031	Common Stock	25,000	\$0.00	25,000		D	

Explanation of Responses:

1. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 24, 2021 or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date.

Remarks:

/s/ Alexander Nguyen,

Attorney-in-Fact for Kristina

06/28/2021

M. Burow

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.